Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006246 · ClinicalTrials.gov registry record · Phase 1
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 8
- Study locations
NCT00006246: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by Pediatric Brain Tumor Consortium.
NCT00006246 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 28 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006246, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 8
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who have refractory CNS cancer and to estimate the maximum tolerated dose of this treatment regimen.
Conditions Studied
Interventions
- DRUG busulfan
Study Locations (8)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
California
- UCSF Cancer Center and Cancer Research Institute - San Francisco
District of Columbia
- Children's National Medical Center - Washington D.C.
Massachusetts
- Dana-Farber Cancer Institute - Boston
North Carolina
- Duke Comprehensive Cancer Center - Durham
Texas
- Baylor College of Medicine - Houston
Washington
- Children's Hospital and Regional Medical Center - Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2000-11 |
| Phase | Phase 1 |
What the finished NCT00006246 record still lists
NCT00006246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower).
The record links to 7 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which busulfan is the first listed.
NCT00006246 lists 8 locations in 7 states (Pennsylvania, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00006246 about?
NCT00006246 is a clinical study titled "Busulfan in Treating Children and Adolescents With Refractory CNS Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who have refractory CNS cancer and to estimate the maximum tolerated dose...
What is the current status of trial NCT00006246?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2000-11.
What conditions does trial NCT00006246 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Sarcoma, Metastatic Cancer, Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00006246?
The interventions under investigation include: busulfan (DRUG).
Who is sponsoring clinical trial NCT00006246?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006246 being conducted?
This trial has 8 study locations across California, District of Columbia, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006246's enrollment target sits among peer trials
28 226th of 299 higher than 73 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia